Evidence map›Paper›PMID 29506548›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.

Maria Teresa Di Martino, Francesca Zazzeroni, Massimo Donadelli, Claudia Chiodoni, Michele Caraglia, Katia Scotlandi, Stefania Meschini, Carlo Leonetti

Registry-linked trialAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05587088 (Evaluation of the Safety and Efficacy of Esperanza Extract), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05587088 phase1 / phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Evaluation of the Safety and Efficacy of Esperanza Extract (Petiveria Alliacea) in Patients With Metastatic Gastrointestinal Tumors and Acute Leukemia

TypeinterventionalSponsorHospital Universitario San IgnacioRan2022 to 2023Enrolled82ConditionsNeoplasm, Stomach, Gastric Neoplasms Malignant, Pancreatic Neoplasms, Colorectal NeoplasmsArmsPetiveria Alliacea Preparation, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Cell communication and signaling: how to turn bad language into positive one.Journal of experimental & clinical cancer research : CR · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Teresa Di MartinoDept. of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy. teresadm@unicz.it.
Francesca ZazzeroniDept. of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Massimo DonadelliDept. of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, Verona, Italy.
Claudia ChiodoniMolecular Immunology Unit, Dept. of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Michele CaragliaDepartment of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy.
Katia ScotlandiExperimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy.
Stefania MeschiniNational Center for Drug Research and Evaluation, National Institute of Health, Rome, Italy.
Carlo LeonettiUOSD SAFU, Regina Elena National Cancer Institute, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCell CommunicationHematologic NeoplasmsHumansImmunomodulationImmunotherapyNeoplasmsPrognosisTreatment OutcomeTumor Microenvironment

Identifiers

PMID29506548
PMCPMC5838855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.